CDH17 and neoplasm: Surprisingly, CDH17-CAR-NK92 cells significantly inhibited ASPC1 tumor burden in mice compared to C9-CAR-NK92 cells, which did not exhibit any tumor inhibition (Fig. 5B, Supporting Information Fig. S10).